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Abstract Mucins are high molecular weight glycoproteins
that play important roles in diagnostic and prognostic
prediction and in carcinogenesis and tumor invasion. Regu-
lation of expression of mucin genes has been studied
extensively, and signaling pathways, transcriptional regula-
tors, and epigenetic modification in promoter regions have
been described. Detection of the epigenetic status of cancer-
related mucin genes is important for early diagnosis of cancer
andformonitoringoftumorbehaviorandresponsetotargeted
therapy. Effects of micro-RNAs on mucin gene expression
have also started to emerge. In this review, we discuss the
current views on epigenetic mechanisms of regulation of
mucin genes (MUC1, MUC2, MUC3A, MUC4, MUC5AC,
MUC5B, MUC6, MUC16,a n dMUC17) and the possible
clinical applications of this epigenetic information.
Keywords Mucin.Cancer.Epigenetics.DNA
methylation.Histone modification.Micro-RNAs
Introduction
Mucins are high molecular weight glycoproteins with
oligosaccharides attached to serine or threonine residues
of the mucin core protein backbone by O-glycosidic
linkages (Hollingsworth and Swanson 2004). These pro-
teins are produced by various types of epithelial cells. In the
past two decades, core proteins for human mucins (MUC1–
MUC8, MUC12–13, MUC15–17, MUC19–21) have been
identified and categorized as membrane-associated mucins
(MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13,
MUC15, MUC16, MUC17, MUC20, and MUC21) and
secreted mucins (MUC2, MUC5AC, MUC5B, MUC6,
MUC7, MUC8, and MUC19) (Chen et al. 2004; Higuchi
et al. 2004; Hollingsworth and Swanson 2004; Itoh et al.
2008; Lehmann et al. 1989; Moniaux et al. 2001). Mucins
are responsible for the physical properties of mucus gels
and are involved in epithelial cell protection and mainte-
nance of the local molecular microenvironment (Bhaskar et
al. 1992; Ho et al. 2006; Linden et al. 2004, 2008).
However, transmembrane mucins, in particular, are overex-
pressed and aberrantly glycosylated in most cases of
adenocarcinoma and are also associated with invasive
proliferation of tumors and a poor outcome (Hollingsworth
and Swanson 2004; Kufe 2009). Immunohistochemical
studies of mucin expression in human tumors have
demonstrated that expression of MUC1 and MUC4 is a
poor prognostic factor, whereas MUC2 expression is
associated with a favorable outcome in neoplasms including
pancreatic ductal adenocarcinomas. MUC5AC is a common
neoplasticmarkerinpancreatobiliaryneoplasms(Nagataetal.
2007; Yonezawa et al. 2008, 2010).
Epigenetic regulation, including DNA methylation, has
been a focus of studies of mucin gene expression. CpG
methylation in genomic DNA plays an important role in
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generally, the promoter region of a transcribed gene is
hypomethylated (Bird 1992). There are three primary DNA
methyltransferases (DNA methyltransferase 1 (DNMT1),
DNMT3A, and DNMT3B). DNMT1 methylates hemi-
methylated DNA and is essential for maintaining methyl-
ation patterns. DNMT3A and DNMT3B target previously
unmethylated CpGs (Oka et al. 2005; Rodriguez-Paredes
and Esteller 2011). Aberrant DNA methylation is strongly
associated with human cancer and may serve as a good risk
marker for future tumor development and as a target for
chemotherapy (Hiraki et al. 2010; Lenhard et al. 2005;
Matsubayashi et al. 2006).
Nucleosomes are the basic unit of DNA packaging in
eukaryotes, and each nucleosome consists of approximately
147 bp DNA and a histone octamer (core histones) (White
et al. 2001). The core histones have an N-terminal amino
acid tail of about 20–35 residues in length that is rich in
basic amino acids (Munshi et al. 2009). Posttranslational
modification of histone tails plays a critical role in
epigenetic silencing (Kondo et al. 2003; Wolffe and Matzke
1999). Histone tails are subject to many different chemical
modifications, including methylation, acetylation, and
phosphorylation (Marmorstein 2001). Such modifications
affect the access of regulatory factors and alter histone
complexes with chromatin, thereby influencing gene ex-
pression. Acetylation of lysines 9, 14, and 27 of histone H3
is associated with euchromatin formation (less condensed),
and acetylation of promoter-proximal histones is associated
with gene expression (Shi et al. 2003). In contrast,
methylation of lysine 9 of histone H3 (H3-MeK9) facili-
tates formation of heterochromatin (highly condensed), and
elevated levels of H3-MeK9 at promoter sequences are
associated with suppression of gene expression (Mutskov
and Felsenfeld 2004; Nguyen et al. 2002). Methylation of
lysine 27 of histone H3 is also a marker for constitutive and
facultative heterochromatin (Alvarez-Venegas and Avramova
2005). Another histone modification, methylation of K4 of
histone H3, localizes to sites of active transcription, and this
modification may stimulate transcription. Combinations of
histone modifications at different residues may act synergis-
tically or antagonistically to affect gene expression (Liang
et al. 2004).
Gene expression may also be regulated by micro-RNAs
(miRNAs), which are a class of small non-coding RNAs of
approximately 22 nucleotides (He and Hannon 2004). In
mammals, miRNAs are incorporated into RNA-induced
silencing complexes and bind imperfectly to the 3′
untranslated region (3′-UTR) of target messenger RNAs
(mRNAs) and repress translation (Nakahara and Carthew
2004). Epigenetic regulation of small non-coding RNAs
plays a critical role in the modulation of mammalian gene
expression (Lujambio and Esteller 2007; Zhang et al.
2008). In addition, miRNAs have been reported to regulate
both tumor suppressor genes and oncogenes (Medina and
Slack 2008; Saito and Jones 2006).
Pathological events such as carcinogenesis can be caused
by alteration in established methylation patterns or dysre-
gulation of chromatin remodeling, both of which can result
in significant and consequential changes in gene expression
(Das and Singal 2004; DeAngelis et al. 2008). Thus,
investigation of DNA methylation, chromatin modification,
and miRNA expression is important for diagnosis of
carcinogenic risk and prediction of outcomes in patients
with cancer.
In this review, we discuss current views on epigenetic
mechanisms of human mucin family genes, and we
examine the possible clinical applications of this epigenetic
information (Table 1).
Analysis of DNA methylation and histone modification
There are two main methods for genome-wide analysis of
DNA methylation patterns, which are referred to as bisulfite
sequencing and MassARRAY analysis. In DNA methylation
analysis, sodium bisulfite is used to distinguish between
methylated and unmethylated cytosine. Bisulfite treatment of
DNAconvertscytosinetouracil,butdoesnotaltermethylated
cytosine. In bisulfite sequencing, polymerase chain reaction
(PCR) amplification of converted DNA is used to replace the
uracil with thymine, and the PCR product is analyzed by
Sanger dideoxy terminator sequencing (Zilberman and
Henikoff 2007). This method is a standard tool in genome-
wide CpG methylation analysis, but is relatively time-
consuming and costly. MassARRAY® quantitative methyla-
tion analysis (Sequenom Inc.) is based on the bisulfite
conversion biochemistry followed by PCR and base-specific
cleavage. The cleavage products are analyzed by matrix-
assisted laser desorption ionization time-of-flight mass spec-
trometry (Ehrich et al. 2005). This combination of methods
gives a highly accurate, sensitive, and high-throughput
approach for quantitative analysis of DNA methylation.
Meanwhile, methylation-specific PCR (MSP), real-time
quantitative MSP with SYBR green or probe (QMSP), and
pyrosequencing can be used for the detection of methyla-
tion status of specific regions involved in the regulation of
gene transcription. MSP and QMSP are bisulfite
conversion-based PCR techniques, in which two PCR
reactions are carried out using unmethylated DNA primers
(U primer) and methylated DNA primers (M primer). MSP
and QMSP are rapid and inexpensive methods for detection
of the CpG methylation status, but only a limited number of
CpGs in a primer sequence can be detected using these
methods. Pyrosequencing is a DNA sequencing technique
that is based on the detection of released pyrophosphate
86 Clin Epigenet (2011) 2:85–96(PPi) during DNA synthesis (Ronaghi 2001). Pyrosequenc-
ing is an accurate and fast method for quantification of CpG
methylation.
Chromatin immunoprecipitation (ChIP) analysis is a
useful technique for investigating histone modifications
and/or protein–DNA interactions. In this procedure,
formaldehyde-treated chromatin nucleoprotein complexes
are sonicated to reduce the sizes of the DNA fragments to
300 to 500 bp. This is followed by immunoprecipitation
using specific antibodies against target histone modifica-
tions or transcriptional factors, with subsequent amplifica-
tion of the immunoprecipitated DNA by PCR (Fullwood
and Ruan 2009).
Functional role and epigenetic regulation mechanisms
of mucin genes
MUC1
The MUC1 transmembrane glycoprotein (gene cluster on
chromosome 1q21) is expressed at a basal level by normal
ductal epithelial cells of secretory organs, including
pancreas, breast, lung, and gastrointestinal tract (Lan et al.
1990), and overexpressed and aberrantly glycosylated in
most cases of adenocarcinoma (Patton et al. 1995). An
elevated level of MUC1 protein plays a role in tumor
progression, especially in the process of metastasis
(Hollingsworth and Swanson 2004;K u f e2009). Our
clinicopathological studies have demonstrated that
MUC1 expression is a poor prognostic factor in various
human neoplasms (Higashi et al. 1999; Kitamura et al.
1996; Sagara et al. 1999; Takao et al. 1999; Tamada et al.
2002; Utsunomiya et al. 1998).
The epigenetic mechanisms of MUC1 were not exam-
ined for more than a decade after initial methylation
analysis of the MUC1 coding region (Zrihan-Licht et al.
1995). However, our recent comprehensive DNA methyl-
ation analysis revealed that MUC1 gene expression is
regulated by DNA methylation and histone H3 lysine 9
(H3-K9) modification at the MUC1 promoter for the first
time (Yamada et al. 2008). In the approximately 3,000 bp of
the MUC1 promoter region, there are 184 CpG sites.
Analysis of all these sites using the MassARRAY compact
system for base-specific cleavage of nucleic acids was
performed in MUC1-positive and MUC1-negative breast,
pancreas, and colon cancer cell lines. The methylation
status of nine CpG sites near the transcriptional start site
and histone H3-K9 modification in the vicinity of the start
site were both related to MUC1 gene expression. Collec-
tively, a series of epigenetic analyses revealed that DNA
demethylation, histone H3-K9 demethylation, and histone
H3-K9 acetylation in the 5′-flanking region of MUC1 might
all be necessary for MUC1 gene expression (Fig. 1). Most
recently, downregulation of MUC1 expression by micro-
RNA has been reported by several groups (Jin et al. 2010;
Rajabi et al. 2010; Sachdeva and Mo 2010). Sachdeva and
Mo showed that miR-145 directly targets MUC1 by
interaction with the 3′-UTR and found that miR-145 acts
as a tumor suppressor in part by affecting invasion and
metastasis by targeting MUC1 (Sachdeva and Mo 2010).
Moreover, Suh et al. found that miR-145 is silenced by
DNA hypermethylation at the miR-145 promoter region in
prostate cancer cells and that 5-azadC treatment induced
miR-145 expression in prostate cancer cell lines with miR-
145 hypermethylation (Suh et al. 2011). In breast cancer
cells, Rajabi et al. indicated that miR-125b suppresses
translation of the MUC1 and that miR-125b thereby
Table 1 CpGs, histone modifications, and other factors or miRNAs that affect the expression of epigenetically regulated mucin genes
Mucins Promoter methylation sites Histone modification Factors or miRNA
MUC1 −70 to +20 H3-me2K9, aceK9 miR-125b, miRNA-145, miR-1226
MUC2 −3,269, −3,199, −2,331,
−1,912, −338 to +158
H3-me2K4, me3K4, meK9, me2K9,
aceK9, me2K27, aceK27, H3-ace,
H4-ace
DNMT1, HDAC2
MUC3A −345 to −75 N.D. N.D.
MUC4 −121 to −81
a H3-ace, me2K9, aceK9, me3K27 Sp1, DNMT3A, DNMT3B, HDAC1,
HDAC3 −170 to −102
b
MUC5AC −3,718 to −3,670 H3-me2K9, aceK9 N.D.
MUC5B −2,677/−2,163 H3-me2K4, me3K4, meK9 DNMT1, HDAC2
−434/−421 me2K9, aceK9, me2K27, aceK27
MUC17 −179 to +52 H3-me2K9, aceK9 N.D.
ND not determined
aRegion reported by Vincent et al.
bRegion reported by Yamada et al.
Clin Epigenet (2011) 2:85–96 87functions as a tumor suppressor (Rajabi et al. 2010). Jin et
al. showed that MUC1 expression is suppressed by miR-
1226 and that miR-1226-induced downregulation of MUC1
is correlated with cell death of MUC1-positive breast
cancer cells (Jin et al. 2010). These findings suggest the
possible functional importance of MUC1 under both
physiological and pathological conditions.
MUC2
MUC2 is a gel-forming secretory mucin that is expressed in
many organs, including the colon, small intestine, and
respiratory tract. The corresponding gene has been mapped
to human chromosome 11p15 (Chang et al. 1994; Desseyn
et al. 1998). Alteration in the protection and lubrication of
the intestinal mucosal surface due to a lack of MUC2 might
induce an increase of bacterial flora with pro-carcinogenic
effects, result in the release of intestinal mucosa-derived
factors that are normally depressed by MUC2-stimulating
pro-carcinogenic factors, or lead to the destruction of the
physical barrier to dietary carcinogens. Loss of MUC2
might also compromise signaling that contributes to
epithelial differentiation and proliferation through contacts
with membrane-bound mucins or alter the differentiation
program of the intestinal mucosa, resulting in an increased
probability of tumor formation. Muc2 knockout mice
frequently develop adenomas in the small intestine that
progress to invasive adenocarcinoma (Velcich et al. 2002).
However, high levels of MUC2 expression seen in indolent
human pancreatobiliary neoplasms (Higashi et al. 1999;
Horinouchi et al. 2003; Nakamura et al. 2002; Yamashita et
al. 1993; Yonezawa et al. 1997) are associated with a
favorable prognosis (Kitamura et al. 1996; Osako et al.
1993; Tamada et al. 2002; Utsunomiya et al. 1998;
Yonezawa et al. 1997, 2008; Yonezawa and Sato 1997).
Epigenetic analysis of the MUC2 gene promoter region
has been widely studied (Gratchev et al. 2001; Hanski et al.
1997; Mesquita et al. 2003; Siedow et al. 2002). We have
determined the detailed methylation status of a wide area of
the MUC2 promoter in breast, lung, pancreas, and colon
cancer cell lines using bisulfite genomic sequencing and
MassARRAY analysis (Hamada et al. 2005; Yamada et al.
2010). Our results indicated that CpG methylation near the
MUC2 transcriptional start site (−338 to +158) plays a
critical role in MUC2 gene expression. ChIP assays were
also performed using anti-dimethyl-H3-K4/K9/K27, anti-
trimethyl-H3-K4/K9, and anti-acetyl-H3-K9/K14/K27 anti-
bodies and revealed that histone H3-K4 methylation,
histone H3-K9 dimethylation, and histone H3-K9/K27
acetylation in the 5′-flanking region of the MUC2 may be
necessary for gene expression (Yamada et al. 2006).
Moreover, treatment with the DNA methylation inhibitor
5-aza-2′-deoxycytidine (5-azadC) and/or a histone deacety-
lase inhibitor, trichostatin A (TSA) decreased the DNA
methylation level in MUC2-negative cells, whereas histone
H3-K4/K9 methylation and H3-K9/K27 acetylation were
changed to the levels in MUC2-positive cells (Yamada et al.
2006). In the distal region of the MUC2 promoter, the CpG
sites at −3,269, −3,199, −2,331, and −1,912 was associated
with expression of MUC2 (Vincent et al. 2007). Vincent et
al. also showed that MUC2 expression is controlled by
HDAC2-enhanced DNMT1 and that methylation of the
MUC2 promoter markedly impaired its activation by the
methylation-insensitive transcription factor SP1 (Vincent et
al. 2007). These studies suggest that epigenetic mechanisms
are tightly correlated with MUC2 expression in epithelial
cells in various organs. Attempts to apply these findings to
clinical samples have begun, and it has been shown that
hypomethylation of MUC2 plays an important role in the
high level of MUC2 expression in mucinous colorectal
cancer (Okudaira et al. 2010).
MUC3A
MUC3A was identified and mapped to a mucin cluster on
chromosome 7q22 and categorized as a membrane-associated
mucin (Crawley et al. 1999; Gum et al. 1990, 1997; Leroy et
al. 2003). An association between MUC3A expression and
poor prognosis has been shown in pancreatic, breast, gastric,
and renal cancers (Leroy et al. 2003;P a r ke ta l .2003;R a k h a
et al. 2005; Wang and Fang 2003). However, little is known
about the functional role of MUC3A in cancer pathology,
and understanding the expression mechanisms of MUC3A
may be a key step in developing new strategies for cancer
diagnosis and treatment.
In the MUC3A proximal promoter (−620 to +209), the
methylation status of 30 CpG sites in breast, lung, pancreas,
and colon cancer cells were examined by MassARRAY
analysis (Kitamoto et al. 2010). The methylation status
showed a good correlation with the level of MUC3A
expression. MUC3A-negative/low cell lines were hyper-
methylated in the vicinity of the transcriptional start site
(−345 to −75), whereas MUC3A-positive cell lines showed
hypomethylation at the same sites. In contrast, restoration
of MUC3A mRNA was observed after TSA treatment,
although there was no correlation of MUC3A expression
with histone modification at H3K4-Me2/Me3 or H3K9-
Me2/Ac. These results suggest that histone H3-K4 and H3-
K9 do not play critical roles in MUC3A regulation.
Although the roles of MUC3A in cancer development are
still unclear, some evidence suggests that MUC3A expres-
sion is associated with a poor prognosis in many tumor
types. Thus, the methylation status of the MUC3A promoter
may be a novel epigenetic marker for the diagnosis of
carcinogenic risk and prediction of outcomes for patients
with cancer.
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MUC4 is a large transmembrane mucin with a very long
glycosylated extracellular domain that is expressed in
various normal tissues. The corresponding gene has been
mapped to a gene cluster at chromosome 3q29 (Audie et al.
1993, 1995; Buisine et al. 1999; Gipson et al. 1999).
MUC4 is often overexpressed in epithelial cancers, as for
MUC1, and is associated with invasive proliferation of
tumors and a poor outcome (Saitou et al. 2005; Shibahara et
al. 2004b; Tamada et al. 2006; Tsutsumida et al. 2007).
MUC4 serves as a intramembrane ligand for the receptor
tyrosine kinase ErbB2, which is a transmembrane glyco-
protein encoded by the c-ErbB-2 proto-oncogene and has a
tyrosine kinase domain that is highly homologous with the
epidermal growth factor receptor (Yamamoto et al. 1986).
Jonckheere et al. (2004) found that treatment with TSA
restored MUC4 mRNA expression in MUC4-negative
pancreatic cancer cells. Singh et al. also showed that the
expression level of MUC4 was restored by treatment with
5-azadC and sodium butyrate, an inhibitor of histone
deacetylase, in MUC4-negative prostate cancer cells, and
suggestedthatMUC4 is regulated epigenetically (Singh et al.
2006). An investigation of the detailed epigenetic mecha-
nisms of MUC4 expression showed that regulation of MUC4
expression involves both DNA methylation (particularly
cytosines at −81, −93, −102, −113, and −121) and histone
H3 modification (including H3-K9 and H3-K27 in the
MUC4 5′-UTR) mediated by DNA methyltransferases
(DNMT3A and DNMT3B) and histone deacetylases
(HDAC1 and HDAC3) in pancreatic and gastric epithelial
cancer cell lines (Vincent et al. 2008). SP1 binding to the
MUC4 promoter (−276/−271 and −166/−156) was also
found to participate in the regulation of MUC4 gene
expression (Vincent et al. 2008).
WeusedquantitativeMassARRAYmethylationanalysisto
examine the methylation status of 92 CpG sites in the MUC4
promoter (−3,629 to +29) in breast, lung, pancreas, and
colon cancer cell lines (Yamada et al. 2009). In 10 cancer
cell lines, methylation of 5 CpG sites in the 5′-flanking
region of MUC4 (−170 to −102) was associated with the
expression of MUC4. Five CpG sites (−121 to −81) had
previously been correlated with the expression of MUC4
in these cells (Vincent et al. 2008), but 2 of these CpG
sites (−93 and −81) were unrelated to expression of MUC4
in our study. This issue may be resolved by the use of
different analytical methods in future studies. Most
recently, an examination of the relationships among
MUC4 promoter methylation, pancreatic cancer progres-
sion, and MUC4 mRNA expression in clinical tissue
samples led to the suggestion that aberrant MUC4
promoter hypomethylation mayb ei n v o l v e di np a n c r e a t i c
carcinogenesis and malignant development of pancreatic
ductal adenocarcinoma (Zhu et al. 2010).
MUC5AC and MUC5B
MUC5AC is a gastric-type secreted gel-forming mucin that
is located in the chromosome 11p15 region in a cluster of
complex mucin genes (Kim et al. 2002). Although
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gastric mucosa served as a positive control for expression,
MUC5AC are never expressed in normal pancreatic tissue.
In contrast, MUC5AC has high de novo expression in many
types of precancerous lesions of pancreatic ductal adeno-
carcinoma (PDAC), including pancreatic intraepithelial
neoplasia (PanIN) (Nagata et al. 2007), intraductal papillary
mucinous neoplasm of the pancreas (Yonezawa et al. 1999),
and mucinous cystic neoplasm of the pancreas (Gratchev et
al. 2001; Handra-Luca et al. 2005). MUC5AC is also
expressed in the lesions of bile duct adenocarcinoma,
including biliary intraepithelial neoplasia, mucin-
producing bile duct tumor, intraductal papillary neoplasm
of the bile duct, and bile duct cystic neoplasm (Shibahara et
al. 2004a; Zen et al. 2006). Thus, MUC5AC expression
may be a useful marker for early detection of pancreato-
biliary neoplasms.
Similar to MUC5AC, MUC5B is also a gel-forming
mucin and the corresponding gene has been mapped to
chromosome 11p15 (Desseyn et al. 1997). MUC5B is
widely expressed in normal tissues in the respiratory and
digestive tract (Andrianifahanana et al. 2001). Little is
known about MUC5B, but aberrant MUC5B expression
has been observed in inflamed or cancerous tissues
(Andrianifahanana et al. 2001; Kamio et al. 2005; Pinto-
de-Sousa et al. 2004).
Previous studies on the epigenetics of human MUC5AC
gene expression have focused on a 1.3-kb promoter region
and found little influence of epigenetic regulation, despite
restoration of MUC5AC mRNA expression in cancer cells
by 5-azadC treatment (Ho et al. 2003; Vincent et al. 2007).
In contrast, a recent study has shown that methylation in the
“CpG island shore” distal to CpG islands is correlated with
silencing of numerous genes (Irizarry et al. 2009). In the
MUC5AC promoter region, there is no CpG site from −1.3
to −3.1 kb, but it is of interest that CpG sites reappear from
about −3.1 kb onwards. This led us to widen the scope of
our study to examine epigenetic mechanisms over about
4.0 kb of the MUC5AC promoter (Yamada et al. 2010). The
DNA methylation status of the MUC5AC promoter (−3,855
to +321) in 10 cancer cell lines (breast, lung, pancreas, and
colon) was mapped using MassARRAY analysis. The
results showed that the CpG methylation status of the
MUC5AC promoter from −3,718 to −3,670 is correlated
with MUC5AC expression. These results were also consis-
tent with data from pyrosequencing analysis. The modifi-
cation status of histone H3-K9 in the distal promoter region
(−3,718 to −3,670) was also tightly correlated with
expression of MUC5AC.
Epigenetic regulation of MUC5B has been shown in
several studies (Perrais et al. 2001; Van Seuningen et al.
2001). Detailed epigenetic analysis of the MUC5B promot-
er region (2.3 kb), including bisulfite sequencing and ChIP
assays, in esophageal, gastric, pancreatic, and colon cancer
cell lines showed that MUC5B is highly sensitive to DNA
methylation and histone modifications in the MUC5B distal
promoter (CpG sites at −2,677/−2,163), as well as at
cytosines at −434 and −421 (Vincent et al. 2007). This
study also indicated that MUC5B expression is regulated by
HDAC2-enhanced DNMT1 and that methylation of the
MUC5B promoter markedly impaired its activation by SP1
(Vincent et al. 2007). Methylation profiling of the MUC5B
distal promoter using bisulfite sequencing and pyrose-
quencing has also been performed in normal lung and in
MUC5B-negative lung cancer tissues (Van Seuningen and
Vincent 2009).
MUC6
MUC6 was originally isolated from a gastric cDNA library
and mapped to a mucin cluster on chromosome 11p15
(Toribara et al. 1993). High expression of MUC6 is
observed in gastric mucosa, duodenal Brunner’s glands,
gall bladder, seminal vesicles, pancreatic centroacinar cells
and ducts, and periductal glands of the common bile duct.
Focal expression is seen in basal endometrial and endocer-
vical glands. MUC6 is also highly expressed in pancreatic
cancers and cholangiocarcinomas and focally expressed in
endocervical adenocarcinomas (Bartman et al. 1998). In
breast tissues, Matsukita et al. have shown a correlation
between MUC6 expression and mucinous carcinoma of the
breast, suggesting that high expression of MUC6, as well as
MUC2, in mucinous carcinoma may act as a barrier to
cancerous growth and result in less aggressive biological
behavior (Matsukita et al. 2003).
Epigenetic regulation of MUC6 seems to be unlikely,
since treatment with 5-aza or TSA did not lead to
restoration of MUC6 mRNA in MUC6-negative cell lines,
despite the identification of three key methylated cytosines
at −282, −271, and −72 by bisulfite sequencing (Vincent et
al. 2007) .V i n c e n te ta l .s u g g e s t e dt h a tr e p r e s s i o no f
MUC6 in cancer cells is rather due to the absence of
necessary transcription factors or by an unknown repres-
sive mechanism than to the methylation of its promoter
(Vincent et al. 2007).
MUC16 (CA125)
MUC16 (CA125) was identified and mapped to a mucin
cluster on chromosome 19p13 and categorized as a
transmembrane mucin (O’Brien et al. 2001). Because
highly O-glycosylated repeats are the landmark of the
mucin family of glycoproteins, CA125 was also named
MUC16. MUC16 is overexpressed in many carcinomas
(e.g., ovarian cancer, uterine cancer, pancreatic cancer,
and biliary cancer) and is known as a tumor marker that
90 Clin Epigenet (2011) 2:85–96is associated with poor prognosis (O’Brien et al. 2001,
2002;Y i na n dL l o y d2001).
The structure and function of MUC16 have been well
studied, but the mechanisms of regulation of MUC16
expression have yet to be clarified. We have examined the
epigenetic status of the MUC16 5′-flanking region in breast,
lung, pancreas, and colon cancer cells using MassARRAY
analysis and ChIP assays (unpublished data). Treatment
with 5-azadC and TSA showed restoration of MUC16
mRNA expression, but MassARRAY and ChIP results
showed no correlation between histone H3 modification
and MUC16 gene expression. Our findings suggest that
epigenetic mechanisms are involved in the regulation of
MUC16 expression in cancer cells, but DNA methylation
and histone H3-K9 modification in the MUC16 5′-flanking
region are unlikely to regulate MUC16 transcription directly.
It will be necessary to perform promoter analysis to clarify
the details of the expression mechanism of MUC16, which is
a poor prognostic factor in patients with cancer.
MUC17
MUC17 glycoprotein was identified and mapped to a mucin
cluster at chromosome 7q22 and categorized as a membrane-
associated mucin (Gum et al. 2002; Williams et al. 1999).
MUC17 is mainly expressed in the digestive tract, including
the duodenum, ileum, and transverse colon (Gum et al.
2002;M o e h l ee ta l .2006), but its physiological function is
unclear. Aberrant MUC17 expression is observed in PDAC,
compared to no expression in the normal pancreas or in
pancreatitis (Moniaux et al. 2006), and MUC17 is an
independent prognostic factor associated with lymph node
metastasis in PDAC (Hirono et al. 2010).
We performed MassARRAY quantitative methylation
analysis in human cancer cell lines (breast, lung, pancreas,
and colon) to determine the methylation status of CpG
islands in the MUC17 5′-flanking region (−620 to +209)
(Kitamoto et al. 2011). Five CpG sites (−179 to +52)
involved in MUC17 expression were identified and these
results were consistent with MSP data. To examine the
relationship between DNA methylation and histone H3
modification, ChIP assays were performed. Dimethyl-H3-
K9 was found in MUC17-negative/low cells, whereas
histone H3-K9 was more highly acetylated in MUC17-
positive cells. The level of MUC17 mRNA expression was
restored by treatment with 5-azadC or TSA. Using MSP
analysis, we also investigated the methylation status of
normal and cancerous pancreatic tissues from patients with
PDAC and found that the methylation status in the five
CpG sites of the MUC17 promoter (−179 to +52) was
consistent with the expression of MUC17 at both the
mRNA and protein levels. Although further studies are
needed to clarify these relationships, our findings indicate
that the methylation status of the MUC17 promoter could
be a novel epigenetic marker for diagnosis of PDAC.
Moreover, miRNA microarray analysis in 11 cancer cell
lines revealed 5 candidates with a significant relationship
with the regulation of MUC17 expression: miR-17, miR-
20a, miR-20b, miR-30c, miR-30e, using target prediction
based on the miRBase. Of these candidates, it is unclear
which are authentic miRNAs in vivo. Additional studies are
required, but our data suggest that the MUC17 gene might
be regulated posttranscriptionally by miRNAs.
Conclusions and clinical perspectives
The epigenetic mechanisms of human mucin family
genes are gradually emerging (Table 1). However,
establishment of clinical tests for cancer screening,
diagnosis of carcinogenic risk, and tumor staging requires
improved understanding of the roles of modifier enzymes
(CpG methylation and chromatin) and epigenetic modifi-
cations accompanying tumor differentiation. An aberrant
increase in both MUC4 mRNA expression and hypome-
thylation frequency in the PanIN–PDAC progression
modality has been shown (Zhu et al. 2010), and increased
DNMT1 expression may be involved in multistage
pancreatic carcinogenesis from the precancerous stage to
malignant progression of ductal carcinomas and may be a
p r e d i c t o ro fp o o rp r o g n o s i s( P e n ge ta l .2005). Further
studies are needed to elucidate the relationships among
expression levels of mucins, binding of transcriptional
regulatory factors, and recruitment of DNMTs, HDACs,
methylated DNA binding domain proteins, and polycomb
group proteins.
Mucin expression is tissue- and cell-type specific
(Yonezawa et al. 2008), and these specificities may cause
different forms of epigenetic regulation at different levels.
For MUC1 and MUC4, we were unable to show a
relationship between DNA methylation status and expres-
sion of MUC1 in the LS174T colon cancer cell line
(Yamada et al. 2008, 2009). However, expression of
MUC1 in Caco2 cells, which are derived from cancer cells
of the same organ, was related to the DNA methylation
status. Similarly, BxPC-3 pancreatic cancer cells with low
MUC5AC expression had a high level of CpG methylation,
whereas PANC1 cells (which have low or no MUC5AC
expression) showed hypomethylation. Our results indicate
that regulation of expression by DNA methylation is not
organ specific, but varies in individual cell lines. Moreover,
coordinated changes in DNA methylation and histone
modification may be important for epigenetic regulation
of mucin genes in cancer cell lines derived from various
organs (Kitamoto et al. 2010, 2011; Yamada et al. 2006,
2008, 2009). However, further studies are needed to clarify
Clin Epigenet (2011) 2:85–96 91how these different epigenetic changes are involved in
tissue-specific mucin expression in cancer.
Many studies of epigenetic gene regulation have
addressed tumor suppressor genes (Garinis et al. 2002).
Meanwhile, evidence for promoter hypomethylation of
oncogenes has gradually emerged in tumors of several
organs (Sato et al. 2003; Sun et al. 2010; Wolff et al. 2010).
Currently, epigenetic regulation of oncogenes is a phenom-
enon of interest. Transmembrane mucin genes associated
with a poor prognosis (e.g., MUC1 and MUC4) may also
be regulated by epigenetic mechanisms. In cancers like
pancreatobiliary and lung carcinomas with a high potential
for malignancy showing MUC1 and MUC4 high expres-
sion but no MUC2 expression (Yonezawa et al. 2008),
promoter CpG sites in transmembrane mucin genes like
MUC1 and MUC4 associated with a poor outcome may be
hypomethylated, while promoter CpG sites of MUC2
associated with a favorable outcome may be hypermethy-
lated, according to the data based on our studies using
human cancer cells (Yamada et al. 2006, 2008, 2009).
Improved understanding of the regulatory mechanisms
controlling these polar opposite events may enhance the
understanding of epigenetic mechanisms associated with
other oncogenes and tumor suppressor genes.
Posttranscriptional regulation of gene expression by
miRNAs is attracting increased attention (Hartmann et al.
2004; Krol et al. 2010; Rajabi et al. 2010). Among mucin
genes, MUC1 expression has been shown to be directly
downregulated by miR-145, with the further finding that
miR-145 acts as a tumor suppressor in cell invasion and
metastasis by targeting MUC1 (Sachdeva and Mo 2010).
miR-125b and miR-1226 have also been reported to target
MUC1 expression (Jin et al. 2010), and it is likely that
these miRNAs could be attractive targets for therapeutic
intervention in advanced cancers.
Epigenetic analysis of cancer-related genes in clinical
specimens is relatively common, especially using DNA
methylation analysis (Kamalakaran et al. 2011;O k u d a i r a
et al. 2010). There are several techniques for the
evaluation of CpG methylation, but MSP, including
quantitative MSP, is a leading strategy for the analysis of
clinical samples (Lee et al. 2009; Zhu et al. 2010).
However, MSP identifies only regions recognized by the
primer sequence, and MassARRAY and pyrosequencing
analysis are increasingly being used to overcome this
problem (Shinojima et al. 2010; Van Seuningen and
Vincent 2009). MassARRAY analysis permits high-
throughput identification of methylation sites and semi-
quantitative measurement at single or multiple CpG sites.
Pyrosequencing is also a reliable technique for quantifi-
cation of methylation at a single CpG site (Brakensiek et
al. 2007). Moreover, methylation analysis by these
technologies gives highly reproducible quantification
(Shinojima et al. 2010; Van Seuningen and Vincent
2009). In these techniques, however, as clinical samples
include various components other than tumor cells,
evaluation of the average percentage of methylation of
the individual CpG sites is not easy. To permit analysis of
discharged fluids, such as pancreatic juice, bile, or sputum,
there is a need to develop the technique that allows the
detection of individual CpG methylation patterns to be
detected.
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